Vioxx - a Victim, Not a Villain

Based on Intercon System's 25 years of experience in data analysis, and following a thorough review of what has been published by the FDA, Intercon believes that Vioxx, Celebrex, Bextra and other non selective NSAIDs, when prescribed and used as labeled, are not a direct contributor to heart attacks or stroke.

(PRWEB) May 7, 2005 -- Politics, Pain and the Torture of the American People.

On April 15, 2005, the FDA posted a 22 page memorandum on the internet, titled "Analysis and recommendations for Agency action regarding non-steroidal anti-inflammatory drugs and cardiovascular risk". Atypically, the memorandum attracted limited attention.

The lengthy FDA document provides the first authorized and authoritative opinion on the issues and questions that were lingering since September 2004, on the cardiovascular risks associated with Vioxx, Celebrex, Bextra and the whole range of NSAIDs drugs. It will soon become the milestone and key document on all future litigation.

The FDA's document also provides insight to the amazing conclusions that led to the dramatic undue recall of Bextra and the nonsensical mandatory labeling requirement on all NSAIDs.

Based upon our 25 years of experience in data analysis, especially 'patient longitudinal data', following a thorough review of what has been published and the FDAs report, Intercon believes that Vioxx, Celebrex, Bextra and other non selective NSAIDs, when prescribed and used as labeled, are an effective pain reliever that are not a direct contributor to heart attacks or stroke.

A white paper, authored by Avi Shatz, the founder, Chairman and CTO of Intercon titled "Politics, Pain and the Torture of the American People" is available for download here:

http://www.targetmedia.com

Or on Intercon's website:

http://www.interconus.com/products_dynatrack.htm

The six page PDF document provides critical analysis and discussion of the FDAs decisions.

About Intercon:

Intercon is a 25-year-old company, specializing in data analysis of large scale databases. It has many of the major pharmaceutical companies as clients, but not Merck or Pfizer. Intercon's DynaTrack software is becoming the Gold Standard for longitudinal (over time) study of patient data. It analyzes data on millions of patients and billions of scripts (prescriptions) rapidly.

Intercon's web site can be reviewed at http://www.interconus.com

Disclaimer:

Intercon has not received or been promised any compensation by Merck, Pfizer or any other major participant in the discussed controversy. None of its officers or employees owns any equity or derivatives in those same companies.

For Further Information Contact: Avi Shatz, in Jerusalem, ISRAEL

US toll free:

1-888-202-9801,

+972 2 653.5496

or by email: avi@ds-dataset.com

# # #